Development and scale-up of the recovery and purification of a domain antibody Fc fusion protein-comparison of a two and three-step approach

ABSTRACT A robust, economical process should leverage proven technology, yet be flexible enough to adopt emerging technologies which show significant benefit. Antibody and Fc‐fusion processes may capitalize on the high selectivity of an affinity capture step by reducing the total number of chromatog...

Full description

Saved in:

Bibliographic Details
Published in:	Biotechnology and bioengineering Vol. 112; no. 7; pp. 1417 - 1428
Main Authors:	Herzer, Sibylle, Bhangale, Atul, Barker, Gregory, Chowdhary, Isha, Conover, Matthew, O'Mara, Brian W., Tsang, Lily, Wang, Shi-Yu, Krystek Jr, Stanley R., Yao, Yan, Rieble, Siegfried
Format:	Journal Article
Language:	English
Published:	United States Blackwell Publishing Ltd 01-07-2015 Wiley Subscription Services, Inc
Subjects:	Additives Affinity Animals Antibodies Biotechnology caprylate CHO Cells Chromatography Chromatography, Liquid - methods Clinical trials Cricetulus design of experiments Fc-fusion protein Immunoglobulin Fc Fragments - genetics Immunoglobulin Fc Fragments - isolation & purification Impurities Pharmacology process development Proteins Purification Recombinant Fusion Proteins - genetics Recombinant Fusion Proteins - isolation & purification Reduction Risk Risk management Risk reduction scale-up Toxicology scale-up caprylate process development Fc-fusion protein purification design of experiments
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	ABSTRACT A robust, economical process should leverage proven technology, yet be flexible enough to adopt emerging technologies which show significant benefit. Antibody and Fc‐fusion processes may capitalize on the high selectivity of an affinity capture step by reducing the total number of chromatographic steps to 2. Risk associated with this approach stems from the potentially increased time frame needed for process development as well as unforeseen changes in impurity profile during first scale‐up of drug substance (DS) for animal toxicology and clinical phase I trials (FIH) production, which could challenge a two‐step process to the point of failure. Two different purification strategies were pursued during process development for an FIH process of a dAB‐Fc fusion protein. A two‐step process was compared to a three‐step process. The two‐step process leveraged additives to maximize impurity reduction during affinity capture. While wash additives in combination with a mixed mode chromatography met all impurity reduction requirements, HCP levels were still higher as compared to the three‐step process. The three‐step process was implemented for manufacture of clinical material to mitigate risk. Biotechnol. Bioeng. 2015;112: 1417–1428. © 2015 Wiley Periodicals, Inc. This works highlights the challenges of working with dAb‐Fc fusion proteins and how changes to the structural components of a full length mAB can create highly curved design spaces due to an altered spatial aggregation propensity profile. It demonstrates an exhaustive exploration of the medium chain length fatty acid based design space pre, during and post Protein A purification and highlights pros and cons of two and three step purification approaches.
Bibliography:	istex:E388BA5CCCD0FDA564AE5D5F9F99C0137386683C ArticleID:BIT25561 ark:/67375/WNG-DX7QD8R2-B ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0006-3592 1097-0290
DOI:	10.1002/bit.25561